NASDAQ:TROV - TrovaGene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2575 0.00 (0.00 %)
(As of 05/24/2018 02:27 AM ET)
Previous Close$0.26
Today's Range$0.2550 - $0.2814
52-Week Range$0.23 - $1.63
Volume1.33 million shs
Average Volume1.69 million shs
Market Capitalization$15.87 million
P/E Ratio-0.48
Dividend YieldN/A
Beta-0.06

About TrovaGene (NASDAQ:TROV)

TrovaGene logoTrovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570

Debt

Debt-to-Equity RatioN/A
Current Ratio2.03
Quick Ratio2.03

Price-To-Earnings

Trailing P/E Ratio-0.48
Forward P/E Ratio-0.99
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales30.58
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book3.22

Profitability

EPS (Most Recent Fiscal Year)($0.54)
Net Income$-24,900,000.00
Net Margins-3,861.57%
Return on Equity-342.47%
Return on Assets-134.39%

Miscellaneous

Employees17
Outstanding Shares59,380,000

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) announced its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. The medical research company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. TrovaGene had a negative return on equity of 342.47% and a negative net margin of 3,861.57%. View TrovaGene's Earnings History.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for TrovaGene.

What price target have analysts set for TROV?

3 brokerages have issued 12-month price targets for TrovaGene's shares. Their forecasts range from $1.00 to $4.00. On average, they expect TrovaGene's stock price to reach $2.50 in the next twelve months. View Analyst Ratings for TrovaGene.

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:
  • 1. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (5/3/2018)
  • 2. Maxim Group analysts commented, "Trovagene announces the initiation of its Phase 2 clinical trial, evaluating the combination of PCM-075 and Zytiga in patients with metastatic Castration- Resistant Prostate Cancer (mCRPC). The study will enroll n=25 patients with mCRPC who are showing early signs of disease progression while on abiraterone/prednisone therapy and will evaluate the proportion of patients achieving disease control after 12 weeks of study treatment. Trovagene still needs to raise capital. The company raised $4.5M in December last year, not enough to achieve critical mass. We downgraded the stock (Nov. 10, 2017) on anticipation that the raise would be dilutive. So while we fundamentally believe in PCM-075, a weak balance sheet still needs to be addressed before we could be more constructive on the outlook for the company." (1/24/2018)

Who are some of TrovaGene's key competitors?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:
  • Mr. William J. Welch, CEO & Director (Age 56)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 58)
  • Dr. Karsten Schmidt Ph.D., Chief Technology Officer (Age 56)
  • Ms. Elizabeth Anderson CPA, VP of Fin. and Admin.
  • Mr. George Samuel J.D., VP & Gen. Counsel

Has TrovaGene been receiving favorable news coverage?

Press coverage about TROV stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TrovaGene earned a news sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $0.2575.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $15.87 million and generates $500,000.00 in revenue each year. The medical research company earns $-24,900,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. TrovaGene employs 17 workers across the globe.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]


MarketBeat Community Rating for TrovaGene (TROV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TrovaGene (NASDAQ:TROV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for TrovaGene in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 870.87%. The high price target for TROV is $4.00 and the low price target for TROV is $1.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.672.672.252.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.50$2.50$3.70$4.60
Price Target Upside: 870.87% upside557.89% upside1,133.33% upside576.47% upside

TrovaGene (NASDAQ:TROV) Consensus Price Target History

Price Target History for TrovaGene (NASDAQ:TROV)

TrovaGene (NASDAQ:TROV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Maxim GroupReiterated RatingHoldLowView Rating Details
3/6/2018HC WainwrightReiterated RatingBuy$1.00HighView Rating Details
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
3/16/2017Piper Jaffray CompaniesDowngradeNeutral ➝ UnderweightHighView Rating Details
3/10/2017S&P Equity ResearchBoost Price Target$1.55 ➝ $1.80N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

TrovaGene (NASDAQ:TROV) Earnings History and Estimates Chart

Earnings by Quarter for TrovaGene (NASDAQ:TROV)

TrovaGene (NASDAQ:TROV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS

TrovaGene (NASDAQ TROV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.09)N/AView Earnings Details
5/8/2018Q1 2018($0.12)($0.09)$0.10 million$0.10 millionViewN/AView Earnings Details
2/26/2018Q4 2017($0.13)($0.06)$0.10 million$0.19 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.14)($0.12)$0.12 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)$0.10 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.26)$0.10 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.31)$0.07 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.32)($0.34)$0.09 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.33)($0.34)$0.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.29)($0.36)$0.34 million$0.12 millionViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$0.14 million$0.08 millionViewListenView Earnings Details
11/9/2015Q3 2015($0.28)($0.37)$0.10 million$0.06 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.41)$0.05 millionViewListenView Earnings Details
5/5/2015($0.23)($0.24)$0.08 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)$0.06 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)$0.05 million$0.06 millionViewN/AView Earnings Details
8/7/2014($0.24)($0.18)$0.05 million$0.06 millionViewN/AView Earnings Details
5/12/2014($0.23)($0.17)$0.05 million$0.11 millionViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.0470 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)$0.29 million$0.04 millionViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)$0.12 million$0.05 millionViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.0340 million$0.1190 millionViewN/AView Earnings Details
4/1/2013Q1 2013($0.10)($0.10)$0.10 million$0.16 millionViewN/AView Earnings Details
11/14/2012Q4 2012($0.05)ViewN/AView Earnings Details
8/15/2012Q3 2012($0.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

TrovaGene (NASDAQ:TROV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

TrovaGene (NASDAQ TROV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 4.52%
Insider Trading History for TrovaGene (NASDAQ:TROV)
Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)

TrovaGene (NASDAQ TROV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/5/2017Stanley TennantDirectorSell8,334$0.69$5,750.46209,394View SEC Filing  
12/19/2016Stanley TennantDirectorBuy10,000$2.10$21,000.00217,728View SEC Filing  
12/16/2016Stanley TennantDirectorBuy14,966$2.00$29,932.00207,728View SEC Filing  
12/16/2016William J WelchCEOBuy4,750$2.09$9,927.502,500View SEC Filing  
12/14/2016Mark ErlanderInsiderBuy5,000$2.08$10,400.005,000View SEC Filing  
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TrovaGene (NASDAQ TROV) News Headlines

Source:
DateHeadline
Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute ...Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute ...
www.prnewswire.com - May 17 at 7:09 PM
BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075
www.reuters.com - May 17 at 7:09 PM
Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid LeukemiaTrovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia
finance.yahoo.com - May 17 at 8:10 AM
Does TrovaGene Inc’s (NASDAQ:TROV) Past Performance Indicate A Stronger Future?Does TrovaGene Inc’s (NASDAQ:TROV) Past Performance Indicate A Stronger Future?
finance.yahoo.com - May 16 at 5:55 PM
Form S-1 Trovagene, Inc.Form S-1 Trovagene, Inc.
www.streetinsider.com - May 11 at 8:08 AM
BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class ...BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class ...
www.reuters.com - May 10 at 8:10 AM
TrovaGene (TROV) Given Hold Rating at Maxim GroupTrovaGene (TROV) Given Hold Rating at Maxim Group
www.americanbankingnews.com - May 9 at 4:59 PM
TrovaGene (TROV) Issues Quarterly  Earnings Results, Beats Estimates By $0.03 EPSTrovaGene (TROV) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 9 at 2:38 PM
Trovagene: 1Q Earnings SnapshotTrovagene: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:07 AM
Trovagene Announces First Quarter 2018 Highlights and Financial ResultsTrovagene Announces First Quarter 2018 Highlights and Financial Results
finance.yahoo.com - May 8 at 5:51 PM
TrovaGene (TROV) Lowered to "Hold" at Zacks Investment ResearchTrovaGene (TROV) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 3 at 10:34 PM
TrovaGene (TROV) Given Average Rating of "Hold" by AnalystsTrovaGene (TROV) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 3 at 8:33 PM
TrovaGene (TROV) Raised to Sell at ValuEngineTrovaGene (TROV) Raised to Sell at ValuEngine
www.americanbankingnews.com - May 2 at 3:48 PM
This Mornings Technical Outlook on Medical Research Stocks -- HTG Molecular Diagnostics, PRA Health Sciences ...This Morning's Technical Outlook on Medical Research Stocks -- HTG Molecular Diagnostics, PRA Health Sciences ...
www.prnewswire.com - May 2 at 8:11 AM
TrovaGene (TROV) Set to Announce Earnings on TuesdayTrovaGene (TROV) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 1 at 5:33 AM
Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with ...Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with ...
www.prnewswire.com - April 17 at 6:06 PM
Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in ...Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in ...
www.prnewswire.com - April 16 at 5:35 PM
Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
finance.yahoo.com - April 16 at 5:35 PM
Maxim Group Reaffirms Hold Rating for TrovaGene (TROV)Maxim Group Reaffirms Hold Rating for TrovaGene (TROV)
www.americanbankingnews.com - April 16 at 1:19 PM
Trovagene, Inc.Trovagene, Inc.
www.streetinsider.com - April 13 at 5:42 PM
Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - April 12 at 5:52 PM
TrovaGene (TROV) Given a $4.00 Price Target at Maxim GroupTrovaGene (TROV) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - April 9 at 11:31 PM
TrovaGene (TROV) Lowered to Strong Sell at ValuEngineTrovaGene (TROV) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 2 at 11:28 PM
Reviewing TrovaGene (TROV) and Its RivalsReviewing TrovaGene (TROV) and Its Rivals
www.americanbankingnews.com - April 2 at 3:06 AM
Form 8-K Trovagene, Inc. For: Mar 20 - StreetInsider.comForm 8-K Trovagene, Inc. For: Mar 20 - StreetInsider.com
www.streetinsider.com - March 21 at 8:27 AM
Trovagene to Present at the 26th Annual Wall Street Investor ConferenceTrovagene to Present at the 26th Annual Wall Street Investor Conference
finance.yahoo.com - March 20 at 8:14 AM
Financial Contrast: TrovaGene (TROV) vs. The CompetitionFinancial Contrast: TrovaGene (TROV) vs. The Competition
www.americanbankingnews.com - March 19 at 3:08 AM
Pre-Market Technical Scan on Medical Research Equities -- HTG Molecular Diagnostics, PRA Health Sciences, Quest ... - PR Newswire (press release)Pre-Market Technical Scan on Medical Research Equities -- HTG Molecular Diagnostics, PRA Health Sciences, Quest ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 7:59 AM
TrovaGene (TROV) Stock Rating Reaffirmed by HC WainwrightTrovaGene (TROV) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 6 at 1:16 PM
TrovaGene up 21% on early results form PMC-075 study ... - Seeking AlphaTrovaGene up 21% on early results form PMC-075 study ... - Seeking Alpha
seekingalpha.com - March 6 at 8:06 AM
Trovagene Announces First Patient Successfully Completes Cycle 1 ... - PR Newswire (press release)Trovagene Announces First Patient Successfully Completes Cycle 1 ... - PR Newswire (press release)
www.prnewswire.com - March 6 at 8:06 AM
Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML TrialTrovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
finance.yahoo.com - March 5 at 8:08 AM
TrovaGene Inc (TROV) Sees Significant Increase in Short InterestTrovaGene Inc (TROV) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM
TrovaGene (TROV) Announces Quarterly  Earnings Results, Beats Estimates By $0.07 EPSTrovaGene (TROV) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - February 27 at 10:14 AM
Trovagene Announces Fourth Quarter and Full-Year 2017 Results - PR Newswire (press release)Trovagene Announces Fourth Quarter and Full-Year 2017 Results - PR Newswire (press release)
www.prnewswire.com - February 27 at 8:08 AM
TrovaGene Inc (TROV) Receives Average Recommendation of "Hold" from BrokeragesTrovaGene Inc (TROV) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 1:52 AM
Trovagene Announces Fourth Quarter and Full-Year 2017 ResultsTrovagene Announces Fourth Quarter and Full-Year 2017 Results
finance.yahoo.com - February 26 at 5:51 PM
BRIEF-Trovagene Announces Activation Of Two Additional Clinical Trial Sites To Conduct Early Stage Leukemia StudyBRIEF-Trovagene Announces Activation Of Two Additional Clinical Trial Sites To Conduct Early Stage Leukemia Study
www.reuters.com - February 13 at 3:37 PM
Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AMLTrovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML
finance.yahoo.com - February 13 at 8:37 AM
Trovagene (TROV) Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer ModelTrovagene (TROV) Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer Model
www.streetinsider.com - February 10 at 3:39 PM
Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers SymposiumTrovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium
finance.yahoo.com - February 9 at 3:46 PM
Trovagene, Inc. - StreetInsider.comTrovagene, Inc. - StreetInsider.com
www.streetinsider.com - February 8 at 8:05 AM
Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)
finance.yahoo.com - February 6 at 8:25 AM
TrovaGene (TROV) Lifted to Sell at ValuEngineTrovaGene (TROV) Lifted to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 12:10 PM
TrovaGene Inc (TROV) Given Average Recommendation of "Hold" by AnalystsTrovaGene Inc (TROV) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 2 at 1:36 AM
Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration ... - PR Newswire (press release)Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration ... - PR Newswire (press release)
www.prnewswire.com - January 25 at 3:37 PM
Trovagene (TROV) Reports Commencement of UNITE Phase 2 Clinical Trial of PCM-075Trovagene (TROV) Reports Commencement of UNITE Phase 2 Clinical Trial of PCM-075
www.streetinsider.com - January 25 at 8:28 AM
Who Owns Most Of TrovaGene Inc (NASDAQ:TROV)?Who Owns Most Of TrovaGene Inc (NASDAQ:TROV)?
finance.yahoo.com - January 25 at 8:28 AM
TrovaGenes (TROV) "Hold" Rating Reaffirmed at Maxim GroupTrovaGene's (TROV) "Hold" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - January 24 at 11:18 PM
BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate CancerBRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer
www.reuters.com - January 24 at 3:44 PM

SEC Filings

TrovaGene (NASDAQ:TROV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TrovaGene (NASDAQ:TROV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TrovaGene (NASDAQ TROV) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.